INTRODUCTION

Fentanyl iontophoretic transdermal system (ITS IONSYS
, The Medicines Company, Parsippany, NJ, USA) is a patient-controlled analgesia (PCA) system indicated for the short-term management of acute postoperative pain in adult patients requiring analgesia [1] . It is worn by the patient on the chest or upper outer arm and is self-adhesive. It employs iontophoresis to deliver fentanyl across intact skin which then diffuses into the systemic circulation and is transported to the central nervous system. When the patient activates a dose by double-pressing a button, the system delivers a dose of fentanyl over a period of 10 min [2] . Fentanyl ITS has a well-documented efficacy and safety profile [3] [4] [5] [6] [7] [8] [9] . It has been shown to be more efficacious than placebo in three Phase III trials [3] [4] [5] and to have similar efficacy to morphine intravenous (IV) PCA in four Phase III trials [6] [7] [8] [9] . It was approved for use The fentanyl ITS system comprises a controller and a drug unit that are snapped together by the health-care professional before being attached to the patient's chest or upper outer arm [2] . The fentanyl ITS drug unit contains no components or materials that could be affected by diagnostic X-rays, computerized tomography (CT) scans or radiofrequency identification (RFID)
transmitters. The fentanyl ITS controller contains semiconductor components that could potentially be affected by radiation from diagnostic X-rays, CT scans or RFID transmitters. The controller has four primary modes of operation as described in Table 1 . ITS and RFID transmitters. In these two studies, the function of the fentanyl ITS was evaluated during and after exposure to X-ray and RFID transmitters to determine whether the prescribed separation distance and the removal precautions are necessary.
MATERIALS AND METHODS
The studies utilized an ITS system without fentanyl, referred to as the ITS Placebo system. The ITS controller contains semiconductor components that could potentially be affected by radiation from X-rays, CT scans or from radiofrequency (RF) energy typical of RFID transmitters. The drug unit was not evaluated since it does not contain any components or materials that could be affected by diagnostic X-rays or RF energy from RFID transmitters. The controller unit used in the ITS Placebo systems is identical to the controller unit in fentanyl ITS.
Study 1: Fentanyl ITS and X-Ray Exposure
The objective of the first study was to evaluate the operational performance of the controller unit when exposed to X-radiation exceeding typical ranges for diagnostic X-rays and CT scans. At the start of the study, the controller and the placebo drug unit were assembled. Once assembled, the green light-emitting The objective of the second study was to determine if the controller unit of the fentanyl ITS maintains operational performance when exposed to RFIDs in direct contact with the The tests were performed using a set of International Organization for Standardization (ISO) and IEC standards that had previously been developed with AIM Healthcare Initiative and the US FDA [10] .
The following frequencies and field strengths representative of RFIDs were tested in direct System performance tests included determining: (1) if the system delivered a dose only when the dosing button was pressed twice within 3 s; (2) if the system delivered an output current less than or equal to the maximum specified current of 195.5 lA; (3) if the dosing interval was equal to or less than 11 min; (4) if the system maintained a dose lockout during the dosing period and (5) if the system provided a dose count equal to or less than the number of doses delivered.
Compliance with Ethics Guidelines
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Study 1: Iontophoretic Transdermal (ITS) Placebo System and X-Ray Exposure
During and following exposure of the ITS Placebo system to each X-ray energy level, all specifications were met and no anomalies were observed. During X-ray exposure there was no output current detected in Ready Mode, and in Dose Mode the output current was in the range from 169.65 to 171.94 lA (nominal target is 170 lA), which is well within specifications (Table 2) . Following X-ray exposure, the ITS Placebo systems remained in Ready Mode and output current was off as expected until the dose button was pressed and released twice within 3 s, when the fentanyl ITS transitioned to Dose Mode, as specified. During Dose Mode after X-ray exposure, additional presses of the dose button had no effect (i.e., the lockout was functioning properly), and output current was in a range from 169.70 to 170.94 lA, which is well within specifications (Table 3) . As expected, the ITS Placebo systems automatically transitioned back to Ready Mode after the specified dose duration, and the output current returned to zero. The Placebo ITS systems automatically transitioned as expected to End-of-Use Mode at 24 h (range 23 h, 57 min to 23 h, 59 min) and then automatically transitioned to End-of-Life Mode 12 h later (range 11 h, 57 min to 11 h, 59 min) as expected. As expected, after entering the End-of-Use and End-of-Life Modes, the system appropriately remained off (i.e., no voltage output). Table 4 ). The ITS Placebo systems automatically transitioned back to Ready Mode after the specified dose duration, and the output current returned to zero as specified (Table 5 ). The Placebo ITS systems automatically transitioned to End-of-Use Mode at the specified 24 h with no output voltage. At this point, the system appropriately remained off as expected.
DISCUSSION
Postoperative patients frequently require X-rays or CT scans. CT scans and radiography work on the same basic principle: an X-ray beam is passed through the body where a portion of the X-rays are either absorbed or scattered by the internal structures, and the remaining X-ray pattern is transmitted to a detector (i.e., film or computer screen) for recording or further processing by a computer [11] . Common diagnostic X-ray and CT systems produce (peak) tube potentials in the range of
25-150 kilovolts (kVp). Evaluations of X-ray
trends (Nationwide Evaluation of X-Ray Trends) indicate that clinical practice utilizes peak tube potentials up to 109 kVp for X-ray and up to 127 kVp for CT scans [12] . Estimates of the effective dose from diagnostic X-ray are in the range of 0.02-8 millisievert (mSv).
Estimates of the effective dose from CT scans are in the range of 2-16 mSv and can vary by a factor of 10 [13] . The results from this study indicate that the fentanyl ITS system will continue to work normally even when exposed to the level of radiation seen in X-rays or CT scans and at a level 259 higher than the typical X-ray and 109 higher than the typical CT scan. In this study, ITS Placebo systems performed as expected in the Ready 
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Mode with the dose current off and in the Dose
Mode when the nominal target dose current of 170 lA was administered for 10 min. It is important to note the ITS continued to operate as expected even though radiation exposure was 109 the normal level. These data support the conclusion that the fentanyl ITS can be used safely and effectively when exposed to diagnostic X-rays or CT scans, and therefore the system does not need to be removed from patients.
However, as with other radio-opaque devices, health-care providers do need to consider placement of the fentanyl ITS and potential X-rays and CT scans, because while radiation does not affect the system, it is radiopaque and therefore could obstruct the X-ray or CT scan image. For example, if a patient needs a chest X-ray postoperatively, it would be advisable to place the system on the arm; conversely, if the patient has some reason to need an upper arm or shoulder X-ray, then the system can be placed on the chest or the opposite arm. The small system size and the site placement options for the system are versatile enough that with some forethought it should not create an issue with radiology. exposures. Therefore, it is critical that any device (including PCA pumps) be compatible with RFID devices; the fentanyl ITS system met all those standards. While the RFID devices are typically situated at some distance from a patient, the current study evaluated the effect of exposure with direct contact to the controller to encompass the most extreme possibility. For all test conditions, the system operated normally in all operating modes including the Ready or Dose Modes. This is especially important as the use of RFID devices in hospitals continues to expand. It is important to note that this study was conducted on the second-generation fentanyl ITS which is the currently marketed system. With the first-generation system, it was determined that the co-packaging of the electronics within the same primary packaging as the hydrogels exposed the electronics to extreme humidity that could potentially damage the electronics and potentially result in self-initiation of the system. The challenges to the first system were unrelated to radiation or RFID. The second-generation system was designed to fully address the earlier issues by separating the hydrogels in the drug unit from the electronic circuit of the controller during manufacture and storage, which removed the primary cause of corrosion and thereby improved reliability [2] . A limitation of this study was that it was conducted in the laboratory versus a hospital setting such that the laboratory data has to be extrapolated to the clinical setting. The study was designed to test the system under conditions that would translate to a hospital setting. In addition, the study tested extreme circumstances to demonstrate a large margin of safety. Specifically, the system was tested with radiation levels that were 259 higher than the typical X-ray and 109 higher than the typical CT scan. For RFID, the system and the RFID were positioned adjacently, while in the hospital some distance would exist. It would not be possible to conduct a study under such conditions utilizing patients, and overall these results inform conditions of use in clinical practice. It is also important to note that this system has been tested in a comprehensive, multi-study Phase 3 clinical program that showed the system to be efficacious with a safety profile consistent with the administration of all opioid medications. [3] [4] [5] [6] [7] [8] [9] Collectively, the clinical and laboratory data provide a set of data that demonstrates the safe and effective use of the fentanyl ITS system.
CONCLUSION
In conclusion, the results of this study support the conclusion that the fentanyl ITS can be used safely and effectively in hospitals utilizing the RFID technology at any distance. Also, the fentanyl ITS is not affected by exposure to radiation levels well beyond those typical of diagnostic X-rays or CT scans. These results should provide added confidence to clinicians that the fentanyl ITS system can be used during X-rays and CT scans as well as in the proximity of RFID devices. 
